{"doi":"10.1002/cnr2.70273","title":"First‐Line Osimertinib for <i>EGFR</i>‐Mutated Squamous Cell Lung Carcinoma: A Case Report","abstract":"<h4>Background</h4>Epidermal growth factor receptor (EGFR) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for EGFR-mutated squamous cell lung carcinoma. We herein present a case of EGFR-mutated squamous cell lung carcinoma that responded to osimertinib.<h4>Case</h4>A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A mass was observed in the left lower lobe on chest CT. Squamous cell lung carcinoma, cT4N1M1b (adrenal metastasis) stage IVA, was diagnosed based on the findings of a CT-guided percutaneous lung biopsy and a CT scan revealing right adrenal metastasis. The primary tumor was subjected to a genomic analysis with the AmoyDx Pan Lung Cancer PCR panel, which revealed an EGFR mutation (exon 21 L858R). The PD-L1 tumor proportion score was 95%. Osimertinib was initiated as first-line targeted therapy. Tumor shrinkage was observed and maintained over 9 months of treatment.<h4>Conclusion</h4>We encountered a rare EGFR-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with EGFR-mutated squamous cell lung carcinoma.","journal":"Cancer Reports","year":2025,"id":4716,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.0398,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-07-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":49677,"name":"Seiya Ichihara","orcid":null,"position":1,"is_corresponding":false},{"id":49678,"name":"Kaori Nii","orcid":null,"position":2,"is_corresponding":false},{"id":49679,"name":"Kazumasa Nanjo","orcid":null,"position":3,"is_corresponding":false},{"id":49680,"name":"Naoki Kadota","orcid":null,"position":4,"is_corresponding":false},{"id":49681,"name":"Yoshio Okano","orcid":null,"position":5,"is_corresponding":false},{"id":49682,"name":"Hisanori Machida","orcid":null,"position":6,"is_corresponding":false},{"id":49683,"name":"Nobuo Hatakeyama","orcid":null,"position":7,"is_corresponding":false},{"id":49684,"name":"Hiroyuki Hino","orcid":null,"position":8,"is_corresponding":false},{"id":49685,"name":"Keishi Naruse","orcid":null,"position":9,"is_corresponding":false},{"id":49686,"name":"Tsutomu Shinohara","orcid":"0009-0000-8750-7098","position":10,"is_corresponding":false},{"id":49687,"name":"Shoji Sakiyama","orcid":null,"position":11,"is_corresponding":false},{"id":49688,"name":"Eiji Tacheuchi","orcid":"0000-0003-1541-9747","position":12,"is_corresponding":false},{"id":49676,"name":"Yugo Matsumura","orcid":null,"position":0,"is_corresponding":true}],"reference_count":16,"raw_metadata":null,"created_at":"2026-03-01T18:20:47.508186Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}